Institute for Asthma and Allergy

Wheaton, Maryland 20902

1 studies enrolling now · 14 studies all time

What they study most

BMM, Bilateral Nasal Polyposis, Bone Marrow Mastocytosis, Chronic Sinusitis With or Without Nasal Polyps, Chronic Spontaneous Urticaria, Hereditary Angioedema, Hereditary Angioedema (HAE), ISM, Mastocytosis, Mastocytosis, Indolent, Mastocytosis, Systemic, SSM

Studies at this site

• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Enrolling by invitation
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis — Running, not enrolling
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Running, not enrolling
• A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE — Completed
• Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) — Completed
• C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks — Completed
• C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks — Completed
• Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) — Completed
• Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) — Completed
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks — Completed
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks — Completed
• Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects — Completed
• Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device — Completed
• Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps — Completed